Available Online: Non-Dilutive Funding Opportunities for Cancer R&D

 

NIH alone awards roughly $6B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle, from basic research, through pre-clinical activities and early phase clinical trials.

In this webinar, we discuss key cancer related opportunities, focusing on the new set of solicitations from the National Cancer Institute (NCI) and the soon to be released CDMRPs (DoD) that are available for life science organizations.

 

View Slide Deck

/0 Comments/by
You might also like
Available Online: Introduction to the SBIR and STTR Funding Mechanisms
Investing in Digital Health
NDFS17 NIDDK NDFS17 Video: The NIDDK SBIR Program: An Overview
How will Congress' $1.5 Trillion Allocations Bill affect Biotech, Medtech, Health-tech, and biopharma Webinar Introducing the SBIR and STTR Funding Opportunities Available Online!
How Non-Dilutive Funding Can Extend Runway in BioPharma, Biotech, and Tech Bio Is Non-Dilutive Funding the Key to Extending Runway in Biopharma and Biotech?
Get 10% off Sachs Associates' 9th Annual Immuno-Oncology Innovation Forum #Sachs_IOIF, June 2, at the Waldorf Astoria Chicago. The programme is designed to discuss key industry trends and milestones on the eve of the ASCO meeting. The event brings together leaders from cancer research institutes, patient advocacy groups, pharma and biotech, and Wall Street, to facilitate partnering, funding and investment. We anticipate around 250 delegates and 25+ company presentations by established and emerging companies with part of the audience participating virtually. We've secured a 10% discount on registration for members of our network. (Just say you're with FreeMind when you register.) There's also a limited number of complimentary passes for qualified institutional (buy/sell-side), private equity, and venture investors. Sachs Associates’ 9th Immuno-Oncology Innovation Forum
NDFS17 NCI NDFS17 Video: NCI Funding & Commercialization Resources for Cancer Tech
How will Congress' $1.5 Trillion Allocations Bill affect Biotech, Medtech, Health-tech, and biopharma How will Congress’ $1.5-Trillion Allocations Bill Affect Life Science R&D?
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *